ICU Stock News & Catalysts – SeaStar Medical

FEATURED

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure

Summary

Nov 4, 2026, 8:41 AM ·Globe Newswire

RECENT

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure

Nov 3, 2026, 8:21 AM ·Globe Newswire

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital

Oct 22, 2026, 12:01 PM ·Globe Newswire

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award

Oct 14, 2026, 8:37 AM ·Globe Newswire

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026

Oct 7, 2026, 8:16 AM ·Globe Newswire

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients

Oct 5, 2026, 8:00 AM ·Globe Newswire

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure

Oct 2, 2026, 9:43 AM ·Globe Newswire

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD

Oct 1, 2026, 8:21 AM ·Globe Newswire

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) --

Sep 29, 2026, 8:36 AM ·Globe Newswire

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute

Sep 24, 2026, 8:16 AM ·Globe Newswire

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ

Sep 10, 2026, 8:35 AM ·Globe Newswire

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal

Aug 12, 2026, 4:05 PM ·Globe Newswire

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure

Aug 6, 2026, 8:35 AM ·Globe Newswire

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical

Jul 14, 2026, 8:34 AM ·Globe Newswire

SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury

Enables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026

Jun 23, 2026, 8:25 AM ·Globe Newswire

SeaStar Medical Holding Corporation ICU · News